Life Technologies blueprints $20M expansion; QVA149 program proffers more PhIII COPD data;

 @FierceBiotech: Open source sizzles in biotech sphere. More | Follow @FierceBiotech

 @JohnCFierce: No surprise AZ is talking up brewing up more deals this year. No surprise they aren't even sticking to their disease focus. | Follow @JohnCFierce

 @RyanMFierce: FDA CIO Eric Perakslis told me that he wants to enable certain agency staff to work more virtually. He's giving more details at Bio-IT World 2012. | Follow @RyanMFierce

 @MarkHFierce: Seeking healthy fat? Then clone a sheep with the right nutrients genetically woven in--via Reuters. Article | Follow @MarkHFierce

> Life Technologies ($LIFE) is budgeting $20 million to expand its cell culture manufacturing facilities in Scotland. Release

> Novartis ($NVS) and Vectura posted more positive late-stage data for their COPD drug QVA149, showing it was superior to GlaxoSmithKline's ($GSK) Seretide. But analysts at Barclays zeroed in on the positive implications for GSK's own rival to QVA149. Story

> Ikaria says Australian regulators have approved Lucassin for HRS 1 patients considered for a liver transplant. Release

Pharma News

 @FiercePharma: More on Novartis' Q2 results, from Bloomberg. Consumer sales tumble 20% on plant closure. News | Follow @FiercePharma

> Diovan rivals, plant woes pinch Novartis profits. Article

> Novartis wants U.K. to quash off-label Avastin use. More

> Watson set to unveil $5.9B Actavis buy, FT reports. Item

Medical Devices News

@FierceMedDev: Orthofix to sell sports-medicine unit for $157.5M | MarketWatch. Story | Follow @FierceMedDev

> Boston Sci heralds Emerge launch in Europe, eyes U.S., other markets. Article

> Illumina results impress despite Roche drama. News

> Orthofix to sell sports medicine unit for $157.5M. Report

Biotech Research News

> Powerful protein halts DNA damage and may block tumors. More

> Johns Hopkins researchers find gene tied to CF secondary complication. Article

> Beyond stem cells: Scientists explore three new paths. Story

> Scientists successfully replicate synthetic DNA. Item

> Nanotech-boosted drug lessens cerebral palsy symptoms in rabbits. News

Pharma Manufacturing News

> Alli sale still held hostage by Roche GMP issues. Item

> Life Technologies expands manufacturing in Scotland. More

> China seizes 77 million tainted drug capsules in crackdown. News

> Merck KGaA manufacturing dodges worst of reductions. Article

> Pfizer, J&J, Abbott facing shortages of crucial ingredients in Pakistan. Story

And Finally… A team of Canadian investigators say that anti-depressants appear to do more harm than good. Release

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.